Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 May;7(5):e008346.
doi: 10.1136/bmjgh-2021-008346.

Prereferral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda

Affiliations
Observational Study

Prereferral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda

Nina C Brunner et al. BMJ Glob Health. 2022 May.

Abstract

Introduction: Children who receive prereferral rectal artesunate (RAS) require urgent referral to a health facility where appropriate treatment for severe malaria can be provided. However, the rapid improvement of a child's condition after RAS administration may influence a caregiver's decision to follow this recommendation. Currently, the evidence on the effect of RAS on referral completion is limited.

Methods: An observational study accompanied the roll-out of RAS in three malaria endemic settings in the Democratic Republic of the Congo (DRC), Nigeria and Uganda. Community health workers and primary health centres enrolled children under 5 years with suspected severe malaria before and after the roll-out of RAS. All children were followed up 28 days after enrolment to assess their treatment-seeking pathways.

Results: Referral completion was 67% (1408/2104) in DRC, 48% (287/600) in Nigeria and 58% (2170/3745) in Uganda. In DRC and Uganda, RAS users were less likely to complete referral than RAS non-users in the pre-roll-out phase (adjusted OR (aOR)=0.48, 95% CI 0.30 to 0.77 and aOR=0.72, 95% CI 0.58 to 0.88, respectively). Among children seeking care from a primary health centre in Nigeria, RAS users were less likely to complete referral compared with RAS non-users in the post-roll-out phase (aOR=0.18, 95% CI 0.05 to 0.71). In Uganda, among children who completed referral, RAS users were significantly more likely to complete referral on time than RAS non-users enrolled in the pre-roll-out phase (aOR=1.81, 95% CI 1.17 to 2.79).

Conclusions: The findings of this study raise legitimate concerns that the roll-out of RAS may lead to lower referral completion in children who were administered prereferral RAS. To ensure that community-based programmes are effectively implemented, barriers to referral completion need to be addressed at all levels. Alternative effective treatment options should be provided to children unable to complete referral.

Trial registrstion number: NCT03568344; ClinicalTrials.gov.

Keywords: child health; health policy; malaria.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Post-referral treatment seeking from a referral health facility (RHF), from other public providers and from non-public providers, for children enrolled before the implementation of rectal artesunate (pre-RAS), and after the implementation of RAS (post-RAS) for RAS non-users and RAS users, by country.
Figure 2
Figure 2
Post-referral treatment seeking from a referral health facility (RHF), from other public providers and from non-public providers for children enrolled before the implementation of rectal artesunate (pre-RAS), and after the implementation of RAS (post-RAS) for RAS non-users and RAS users, by enrolment location, in DRC and Nigeria. CHW, community health worker; DRC, Democratic Republic of the Congo; PHC, primary health centre.
Figure 3
Figure 3
Timely referral completion on the same or next day after referral by a community-based provider, from all patients completing referral to a referral health facility, for children enrolled before the implementation of rectal artesunate (pre-RAS), and after the implementation of RAS (post-RAS) for RAS non-users and RAS users, by country. DRC, Democratic Republic of the Congo.

Similar articles

Cited by

References

    1. Gomes MF, Faiz MA, Gyapong JO, et al. . Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009;373:557–66. 10.1016/S0140-6736(08)61734-1 - DOI - PMC - PubMed
    1. Global Malaria Programme . Rectal artesunate for pre-referral treatment of severe malaria. Geneva: World Health Organization; 2017.
    1. Simba DO, Kakoko DC, Warsame M, et al. . Understanding caretakers' dilemma in deciding whether or not to adhere with referral advice after pre-referral treatment with rectal artesunate. Malar J 2010;9:123. 10.1186/1475-2875-9-123 - DOI - PMC - PubMed
    1. Gomes M, Ribeiro I, Warsame M, et al. . Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect Dis 2008;8:39. 10.1186/1471-2334-8-39 - DOI - PMC - PubMed
    1. World Health Organization . Guidelines for the treatment of malaria - 3rd edition. Geneva: World Health Organization; 2015.

Publication types

Associated data